By Tristan Wilkins, Head of Process Engineering, Biologics, and Jeffrey Robinson, Associate Director, MSAT, Lonza P&B
Over the last decade, we have witnessed our industry going through significant changes that have drastically transformed the traditional biopharma business model. Biomanufacturers must now adopt new strategies that allow them to develop and manufacture a wide range of products while still delivering safe and effective drugs at the highest level of quality. Single-use technology (SUT) is facilitating this transition by enabling flexibility and efficiency. Yet, meeting the needs of the modern biomanufacturing landscape calls for more than just implementing SUT; instead, it requires a combination of technology and digital solutions working together to effectively and efficiently meet your goals.